These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

472 related articles for article (PubMed ID: 32824865)

  • 1. Application of Anti-Inflammatory Agents in Prostate Cancer.
    Hatano K; Fujita K; Nonomura N
    J Clin Med; 2020 Aug; 9(8):. PubMed ID: 32824865
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Main Inflammatory Cells and Potentials of Anti-Inflammatory Agents in Prostate Cancer.
    Hayashi T; Fujita K; Matsushita M; Nonomura N
    Cancers (Basel); 2019 Aug; 11(8):. PubMed ID: 31408948
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Suppressive role of myeloid-derived suppressor cells (MDSCs) in the microenvironment of breast cancer and targeted immunotherapies.
    Shou D; Wen L; Song Z; Yin J; Sun Q; Gong W
    Oncotarget; 2016 Sep; 7(39):64505-64511. PubMed ID: 27542274
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pro-Tumoral Inflammatory Myeloid Cells as Emerging Therapeutic Targets.
    Szebeni GJ; Vizler C; Nagy LI; Kitajka K; Puskas LG
    Int J Mol Sci; 2016 Nov; 17(11):. PubMed ID: 27886105
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Myeloid-Derived Suppressor Cells: Critical Cells Driving Immune Suppression in the Tumor Microenvironment.
    Parker KH; Beury DW; Ostrand-Rosenberg S
    Adv Cancer Res; 2015; 128():95-139. PubMed ID: 26216631
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effective combinatorial immunotherapy for castration-resistant prostate cancer.
    Lu X; Horner JW; Paul E; Shang X; Troncoso P; Deng P; Jiang S; Chang Q; Spring DJ; Sharma P; Zebala JA; Maeda DY; Wang YA; DePinho RA
    Nature; 2017 Mar; 543(7647):728-732. PubMed ID: 28321130
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Inflammation and Myeloid Cells in Cancer Progression and Metastasis.
    Deng J; Fleming JB
    Front Cell Dev Biol; 2021; 9():759691. PubMed ID: 35127700
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Myeloid suppressor cells in cancer and autoimmunity.
    Sica A; Massarotti M
    J Autoimmun; 2017 Dec; 85():117-125. PubMed ID: 28728794
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Myeloid-derived suppressor cells and tumor: Current knowledge and future perspectives.
    Safari E; Ghorghanlu S; Ahmadi-Khiavi H; Mehranfar S; Rezaei R; Motallebnezhad M
    J Cell Physiol; 2019 Jul; 234(7):9966-9981. PubMed ID: 30537008
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The Role of Myeloid-Derived Suppressor Cells (MDSC) in Cancer Progression.
    Umansky V; Blattner C; Gebhardt C; Utikal J
    Vaccines (Basel); 2016 Nov; 4(4):. PubMed ID: 27827871
    [TBL] [Abstract][Full Text] [Related]  

  • 11. TLR9 expression and secretion of LIF by prostate cancer cells stimulates accumulation and activity of polymorphonuclear MDSCs.
    Won H; Moreira D; Gao C; Duttagupta P; Zhao X; Manuel E; Diamond D; Yuan YC; Liu Z; Jones J; D'Apuzzo M; Pal S; Kortylewski M
    J Leukoc Biol; 2017 Aug; 102(2):423-436. PubMed ID: 28533357
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Immunological Approaches Towards Cancer and Inflammation: A Cross Talk.
    Qu X; Tang Y; Hua S
    Front Immunol; 2018; 9():563. PubMed ID: 29662489
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Acetyl-L-Carnitine downregulates invasion (CXCR4/CXCL12, MMP-9) and angiogenesis (VEGF, CXCL8) pathways in prostate cancer cells: rationale for prevention and interception strategies.
    Baci D; Bruno A; Cascini C; Gallazzi M; Mortara L; Sessa F; Pelosi G; Albini A; Noonan DM
    J Exp Clin Cancer Res; 2019 Nov; 38(1):464. PubMed ID: 31718684
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Use of Non-steroidal Anti-inflammatory Drugs for Chemoprevention of Inflammation-induced Prostate Cancer.
    Debeleç Bütüner B; Öztürk MB
    Turk J Pharm Sci; 2017 Dec; 14(3):274-279. PubMed ID: 32454624
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Notch Signaling in Myeloid Cells as a Regulator of Tumor Immune Responses.
    Hossain F; Majumder S; Ucar DA; Rodriguez PC; Golde TE; Minter LM; Osborne BA; Miele L
    Front Immunol; 2018; 9():1288. PubMed ID: 29915603
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Paving the Road to Tumor Development and Spreading: Myeloid-Derived Suppressor Cells are Ruling the Fate.
    Meirow Y; Kanterman J; Baniyash M
    Front Immunol; 2015; 6():523. PubMed ID: 26528286
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Myeloid-Derived Suppressor Cells as Key Players and Promising Therapy Targets in Prostate Cancer.
    Siemińska I; Baran J
    Front Oncol; 2022; 12():862416. PubMed ID: 35860573
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Myeloid-derived suppressor cells: Roles in the tumor microenvironment and tumor radiotherapy.
    Yin Z; Li C; Wang J; Xue L
    Int J Cancer; 2019 Mar; 144(5):933-946. PubMed ID: 29992569
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Nanoparticle Systems Modulating Myeloid-Derived Suppressor Cells for Cancer Immunotherapy.
    Wilkerson A; Kim J; Huang AY; Zhang M
    Curr Top Med Chem; 2017; 17(16):1843-1857. PubMed ID: 27875974
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Obesity, Inflammation, and Prostate Cancer.
    Fujita K; Hayashi T; Matsushita M; Uemura M; Nonomura N
    J Clin Med; 2019 Feb; 8(2):. PubMed ID: 30736371
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 24.